Goldman Sachs is out with its report today on Johnson & Johnson JNJ, maintaining Buy.
In a note to clients, Goldman Sachs writes, "We continue to see JNJ as the best underappreciated new product story in
Pharma, with the only accelerating earnings trajectory over the next three years across the global sector. Fueled by an emerging pipeline in Pharma, stabilization in MD&D and bottoming out in Consumer, we see acceleration to 9%-10% EPS growth over the next three years from the 2-3% over the
last two years."
At the time of posting, shares of JNJ were trading pre-market at $66.00, down 0.24% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in